Retratrutide 40mg

Description

Retratrutide 40mg represents the next generation of metabolic therapy. Developed by Eli Lilly, it’s designed to activate three key hormone pathways—GLP-1, GIP and glucagon—to improve blood sugar control, increase fat burning, and promote significant weight loss.

How It Works

Retatrutide mimics the action of:

• GLP-1: boosts insulin secretion and suppresses appetite

• GIP: enhances insulin sensitivity and metabolic balance

• Glucagon: increases energy expenditure and lipid oxidation

By combining these three mechanisms, Retatrutide may deliver greater total weight reduction than existing GLP-1 or dual-agonist drugs such as Mounjaro (tirzepatide).

Clinical Highlights

• Phase 2 trial results published in The New England Journal of Medicine show up to 24 % mean body-weight reduction after 48 weeks.

• Demonstrated substantial improvement in fasting glucose and HbA1c among type 2 diabetes participants.

• Generally well tolerated; side effects mainly mild-to-moderate gastrointestinal (nausea, vomiting).

• Currently in Phase 3 clinical trials for obesity and diabetes.
  (Source – NEJM study)

Dosage & Administration

• Investigated as a once-weekly subcutaneous injection

• Dose range 2 mg – 12 mg (under study)

• Not yet approved for commercial use

Potential Benefits

• May exceed 20 % average weight loss

• Improves insulin sensitivity and glucose control

• Enhances energy expenditure

• Could address obesity, type 2 diabetes and liver metabolic disorders simultaneously

Retratrutide 40mg Side Effects

• Nausea / vomiting / diarrhea (common, dose-dependent)

• Mild fatigue or decreased appetite in early treatment

• No serious safety signals to date (based on Phase 2 data)

Storage & Form (anticipated)

• Single-use pre-filled pen for once-weekly injection (expected format)

• Keep refrigerated prior to use (standard GLP-1 storage conditions)